

Curriculum vitae

Passionate Biomedical Doctor with +10 years in the Nuclear Medicine and Radiopharmacy field with assorted competence in clinical routine, research and teaching.

Employment History

Director of the Radiopharmacy	<i>Hôpitaux Universitaire de Bruxelles (Institut Jules Bordet, Hôpital Erasme, HUDERF)</i>	Januari 2023-ongoing
Professor of Radiopharmacy and Radiochemistry	<i>Université Libre de Bruxelles</i>	2017-ongoing
Radiopharmacy Manager (Clinical routine)	Jules Bordet Institut	Nov. 2010-Januari 2023
Biomedical Doctor (Research)	Jules Bordet Institut	Nov. 2010-Januari 2023
Quality Assurance officer	Brussels Imaging Pharmacy	2017-march 2023
Clinical Research Associate	Jules Bordet Institut	Oct. 2009- Nov. 2010
Research assistant	Vrije Universiteit Brussel	Sep. 2008-Oct. 2009

Education

Executive MBA	Solvay Business School	2020-2022
PhD in the Pharmaceutical and Biomedical Sciences	Université Libre de Bruxelles	2010-2015
Master in Biomedical Imaging	Universiteit Antwerpen	2007-2008
Master in Biomedical Sciences	Universiteit Antwerpen	2002-2007
High school degree: Science-Mathematics	St. Norbertus Instituut Antwerp	2002

References

Available up on request

Communications and publications

Annexe CV_Com&Pub



Surname: Wimana
First name: Zéna (usual and preferred); Léna (Legal)
Birthplace: Kinshasa (DRC)
Birthdate 03/05/1984
Nationality: Belgium



+32 (0) 2 541 3997
(0) 497 711 899



Brussels, Belgium



zena.wimana@hubruxelles.be

Skills

- Communication skills
- Organizational know-how
- Problem solving abilities
- Leadership experience
- Scope Management

Languages

- French: mother tongue
- Dutch: second language (education language)
- English: fluently speaking and good writing

Communications and publications
--

Original Articles

- Disturbing the Redox Balance Using Buthionine Sulfoximine Radiosensitized Somatostatin Receptor-2 Expressing Pre-Clinical Models to Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu-DOTATATE. Delbart W, Marin G, Stamatopoulos B, de Wind R, Sirtaine N, Demetter P, Vercruyssen M, Woff E, Karfis I, Ghanem GE, Flamen P, **Wimana Z**. *Cancers*. 2023 Apr 17;15(8):2332. doi: 10.3390/cancers15082332.
- Understanding the Radiobiological Mechanisms Induced by ¹⁷⁷Lu-DOTATATE in Comparison to External Beam Radiation Therapy. Delbart W, Karabet J, Marin G, Penninckx S, Derrien J, Ghanem GE, Flamen P, **Wimana Z**. *Int J Mol Sci*. 2022 Oct 15;23(20):12369. doi: 10.3390/ijms232012369.
- Everolimus-induced somatostatin receptor overexpression in a rectal neuroendocrine tumor patient may promote somatostatin receptor-guided radionuclide therapy (peptide receptor radiotherapy) as an additional treatment option. Mileva M, **Wimana Z**, Flamen P, Karfis I. *World J Nucl Med*. 2020 Oct 23;20(3):316-318. doi: 10.4103/wjnm.
- Downregulation of the FTO m6A RNA demethylase promotes EMT-mediated progression of epithelial tumors and sensitivity to Wnt inhibitors. Jeschke J, Collignon E, Al Wardi C, Krayem M, Bizet M, Jia Y, Garaud S, **Wimana Z**, ..., Jean-Christophe Marine & François Fuks. *Nat Cancer*. 2021 Jun;2(6):611-628. doi: 10.1038/s43018-021-00223-7
- Investigating intrinsic radiosensitivity biomarkers to peptide receptor radionuclide therapy with [¹⁷⁷Lu]Lu-DOTATATE in a panel of cancer cell lines. Delbart W, Ghanem G, Karfis I, Flamen P, **Wimana Z**. *Nucl Med Biol*. May-Jun 2021;96-97:68-79. doi: 10.1016/j.nucmedbio.2021.03.006.
- ⁶⁸Ga-PSMA PET/CT-based metastasis-directed radiotherapy for oligometastatic prostate cancer recurrence after radical prostatectomy. Artigas C, Flamen P, Charlier F, Levillain H, **Wimana Z**, Diamand R, Albisinni S, Gil T, Velthoven RV, Peltier A, Gestel DV, Roumeguere T, Otte FX. *World J Urol*. 2019 Aug;37(8):1535-1542.
- Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle. Bartelink IH, Jones EF, Shahidi-Latham SK, Lee PRE, Zheng Y, Vicini P, van 't Veer L, Wolf D, Iagaru A, Kroetz DL, Prideaux B, Cilliers C, Thurber GM, **Wimana Z**, Gebhart G. *Clin Pharmacol Ther*. 2019 Jul;106(1):148-163.
- N-Acetylcysteine breaks resistance to trastuzumab caused by MUC4 overexpression in human HER2 positive BC-bearing nude mice monitored by ⁸⁹Zr-Trastuzumab and ¹⁸F-FDG PET imaging. **Wimana Z**, Gebhart G, Guiot T, Vanderlinden B, Larsimont D, Doumont G, Van Simaey G, Goldman S, Flamen P, Ghanem G. *Oncotarget*. 2017 Apr 10;8(34):56185-56198.
- Value of the ⁶⁸Ga-DOTATATE PET-CT in the diagnosis of endometriosis. A pilot study. Fastrez M, Artigas C, Sirtaine N, **Wimana Z**, Caillet M, Rozenberg S, Flamen P. *Eur J Obstet Gynecol Reprod Biol*. 2017 May;212:69-74.
- Accuracy and precision assessment for activity quantification in individualized dosimetry of ¹⁷⁷Lu-DOTATATE therapy. Marin G, Vanderlinden B, Karfis I, Guiot T, **Wimana Z**, Flamen P, Vandenberghe S. *EJNMMI Phys*. 2017 Dec;4(1):7.
- Imaging Diagnostic and Therapeutic Targets: Human Epidermal Growth Factor Receptor 2. Gebhart G, Flamen P, De Vries EG, Jhaveri K, **Wimana Z**. *J Nucl Med*. 2016 Feb; 57 Suppl 1:81S-8S
- Mucolytic Agents Can Enhance HER2 Receptor Accessibility for [(⁸⁹Zr)]Trastuzumab, Improving HER2 Imaging in a Mucin-Overexpressing Breast Cancer Xenograft Mouse Model. **Wimana Z**, Gebhart G, Guiot T, Vanderlinden B, Morandini R, Doumont G, Sherer F, Van Simaey G, Goldman S, Ghanem G, Flamen P. *Mol Imaging Biol*. 2015 Oct;17(5):697-703.

- Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR Trial. Gebhart G, Lamberts LE, **Wimana Z**, Garcia C, Emonts P, Ameye L, Stroobants S, Huizing M, Aftimos P, Tol J, Oyen WJ, Vugts DJ, Hoekstra OS, Schröder CP, Menke-van der Houven van Oordt CW, Guiot T, Brouwers AH, Awada A, de Vries EG, Flamen P. Ann Oncol. 2015 Nov 23
- Paget bone disease demonstrated on 68Ga-PSMA ligand PET/CT. Artigas C, Alexiou J, Garcia C, **Wimana Z**, Otte FX, Gil T, Van Velthoven R, Flamen P. Eur J Nucl Med Mol Imaging. 2015 Oct 27
- Preliminary in vivo evaluation of [131I]-2-iodo-D-phenylalanine as a potential radionuclide therapeutic agent in R1M-fluc rhabdomyosarcoma tumor-bearing NuNu mice using bioluminescent imaging. Bauwens M, **Wimana L**, Keyaerts M, Peleman C, Lahoutte T, Kersemans K, Snykers S, Vinken M, Mertens J, Bossuyt A. Cancer Biother Radiopharm. 2010 Apr; 25(2):225-31.

Book

- A TECHNOLOGIST'S GUIDE, RADIOPHARMACY: AN UPDATE. Chapter 2: Theoretical Basics of Radiopharmacy, Zéna Wimana, 18-29.

Abstracts

- Theoretical Basics of Radiopharmacy. **Wimana Z**. 2019. Eur J Nucl Med Mol Imaging (2019) 46 (Suppl 1): S165
- Labelling and Dispensing of Therapeutic Radiopharmaceuticals. **Wimana Z**. 2018. Eur J Nucl Med Mol Imaging (2018) 45 (Suppl 1): S27
- One-step radiosynthesis of ⁶⁸Ga-DKFZ-PSMA-11 at room temperature. **Wimana Z**, Artigas C, Flamen P, Ghanem G. 2015. European Journal of Nuclear Medicine and Molecular Imaging 42 (Suppl1):S173
- Mucolytic agents can enhance HER2 receptor accessibility for ⁸⁹Zr-trastuzumab, improving HER2-imaging in a mucin-overexpressing breast cancer xenograft mouse model. **Wimana Z**, Gebhart G, Guiot T, Vanderlinden B, Morandini R, Doumont G, Sherer F, Van Simaey G, Goldman S, Ghanem G, Flamen P. J Nucl Med 2015 56:120
- Mucolytic drug N-Acetylcystein improves ⁸⁹Zr-trastuzumab HER2-immunoPET imaging by restoring accessibility to HER2 hampered by membrane mucin overexpression in a HER2 positive MUC4 overexpressing xenograft mouse model. **Wimana Z**, Gebhart G, Morandini R, Flamen P and Ghanem G. Cancer Res, October 1, 2014 74:4924
- PET/CT with ⁸⁹Zr-trastuzumab and ¹⁸F-FDG to individualize treatment with trastuzumab emtansine (T-DM1) in metastatic HER2-positive breast cancer (mBC). G. Gebhart, L.E. Lamberts, C. Garcia, L. Ameye, S. Stroobants, M. Huizing, P. G. Aftimos, Jolien Tol, Wim J.G. Oyen, **Z. Wimana**, G.A.M.S. van Dongen, O.S. Hoekstra, C. P. Schroder, J. Gaye, C. W. Menke, T. Guiot, A. H. Brouwers, A.Awada, E.G. E. de Vries, P. Flamen. J Clin Oncol 32:5s, 2014 (suppl; abstr 11001).
- Interference of mucin in the binding of ⁸⁹Zr-trastuzumab on HER2 receptor and influence of mucolytic agents in the HER2 positive MUC4 overexpressing trastuzumab resistant JIMT1 cell line. **Wimana Z**, Gebhart G, Morandini R, Flamen P, and Ghanem G-E. J. NUCL. Med. May 2012; 53: 1718.

Invited Oral Presentations

- QC in Radiopharmacy. BELNUC Technologist day meeting, 2013.
- Gallium 68 ligands and tracers. BELNUC congress, 2015.
- Gallium-68 produced by cyclotron vs generator: pros & cons. BELNUC congress, 2019

- Le radiomarquage, QC et la délivrance des theranostics. Congrès maghrébin de médecine nucléaire, 2019.
- Diagnostic and therapeutic strategies in the fight against cancer. Belgian Side Event on the margin of the IAEA General Conference, 2019.
- Establishing radio ligand imaging and therapy in hospital practice. EANM congress, 2022
- The way to radiotheranostics: IJB as a center of excellence. EPSM congress, 2022
- Théranostique: l'importance capitale de la médecine nucléaire. GEMENU conférence 2023

Other: Redaction/Submission dossier to the Belgian Federal competent authorities (FAMHP/FANC)

- Investigational Medicinal Product Dossier (IMPD):
 - IMPD of ⁸⁹Zr-Trastuzumab. **Wimana Z**, Gebhat G, Ghanem G. 2011
 - IMPD of ⁸⁹Zr-Rituximab. Vaes M, **Wimana Z**, Ghanem G. 2012
 - IMPD of ⁹⁰Y-Rituximab. Vaes M, **Wimana Z**, Ghanem G. 2012
 - IMPD of ¹⁷⁷Lu-DOTATATE. **Wimana Z**, Karfis I, Ghanem G. 2013
 - IMPD of ⁶⁸Ga-DOTATATE. **Wimana Z**, Ghanem G. 2016
- Production dossier of Radiopharmaceuticals (Demande d'inscription dans la liste des produits radio-pharmaceutiques remboursables, Demande d'Autorisation de Production, Notice d'utilisateur)
 - Production dossier of ⁶⁸Ga-DOTATATE. **Wimana Z**, Ghanem G. 2016
 - Production dossier of ⁶⁸Ga-PSMA. **Wimana Z**, Ghanem G. 2016
 - Production dossier of ¹⁷⁷Lu-DOTATATE. Renguét M, **Wimana Z**. 2019
 - Production dossier of ¹⁷⁷Lu-PSMA. **Wimana Z**, Renguét M. 2020
 - Production dossier of ⁶⁸Ga-FAPI. Vercauteren S, **Wimana Z**. 2023